BREAKING NEWS!: FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer. Read More.
Go here to learn more or to get a mailed copy.
Home » Take Action » PCF 3P Report 2018
To test the public’s knowledge/perception about prostate cancer, the PCF surveyed more than 2,000 adult men and women 18 and older (Millennials, Gen-Xers and Boomers) from across the U.S. Download the full report here. Some key findings: